Five Late-Stage Products In Lilly’s Pipeline Could Launch By End Of Decade
This article was originally published in The Pink Sheet Daily
Executive Summary
Mid- and late-stage pipeline opportunities, including gamma secretase inhibitor for Alzheimer’s and long-acting versions of Byetta and Zyprexa, fuel Lilly’s optimism.